DOI: https://doi.org/10.22141/2224-0713.1.103.2019.158638

Features of cognitive impairment in patients with multiple sclerosis

O.O. Kopchak, T.A. Odintsova

Abstract


The article deals with the cognitive impairment, which is characteristic of the different types of multiple sclerosis course. The risk factors of their development or progression, the diagnostic aspects are described. The influence of pathogenetic and symptomatic treatment, lifestyle management and rehabilitation are considered.

Keywords


multiple sclerosis; cognitive impairment; risk factors; diagnosis; pharmacological correction

References


Dubois B., Kobelt G., Berg J., Capsa D., Gannedahl M. New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium // Multiple Sclerosis Journal. — 2017. — 23(25). — P. 29-40. DOI: 10.1177/1352458517708100.

Strober L.B., Rao S.M., Lee J.C. et al. Cognitive impairment in multiple sclerosis: an 18 year follow-up study // Multiple Sclerosis and Related Disorders. — 2014. — 3. — P. 473-481. DOI: 10.17925/ENR.2015.10.02.157.

McNicholas N., O’Connell K., Yap S.M., Killeen R.P., Hutchinson M., McGuigan C. Cognitive dysfunction in early multiple sclerosis: a review // QJM: An International Journal of Medicine. — 2018. — 111(6). — P. 359-364. DOI: 10.1093/qjmed/hcx070.

Pitteri M., Romualdi C., Magliozzi R., Monaco S., Cala­brese M. Cognitive impairment predicts disability progression and cortical thinning in MS: An 8-year study // Multiple Sclerosis. — 2017. — 23(6). — P. 848-854. DOI: 10.1177/1352458516665496.

De Medeiros Rimkus C., Steenwijk M.D., Frederik Barkhof F. Causes, effects and connectivity changes in MS-related cognitive decline // Dement. Neuropsychol. — 2016. — 10(1). — P. 2-11. DOI: 10.1590/S1980-57642016DN10100002.

Lucas R.M., Ponsonby A.L., Dear K. et al. Sun exposure and vitamin D are independent risk factors for CNS demyelination // Neurology. — 2011. — 76. — P. 540-548. DOI: 10.1212/WNL.0b013e31820af93d.

Rimkus C.M., Steenwijk M.D., Barkhof F. Causes, effects and connectivity changes in MS-related cognitive decline // Dementia & Neuropsychologia. — 2016. — 10(1). — P. 2-11. DOI: 10.1590/S1980-57642016DN10100002.

Prokopova B., Hlavacova N., Vlcek M., Penesova A., Grunnerova L., Garafova A., Turcani P., Kollar B., Jezova D. Early cognitive impairment along with decreased stress-induced BDNF in male and female patients with newly diagnosed multiple sclerosis // Journal of Neuroimmunology. — 2017. — 15(302). — P. 34-40. DOI: 10.1016/j.jneuroim.2016.11.007.

Patanella A.K., Zinno M., Quaranta D., Nociti V., Frisullo G., Gainotti G., Tonali P.A., Batocchi A.P., Marra C. Correlations between peripheral blood mononuclear cell production of BDNF, TNF-alpha, IL-6, IL-10 and cognitive performances in multiple sclerosis patients // Journal of Neuroscience Research. — 2010. — 88(5). — P. 1106-1112. DOI: 10.1002/jnr.22276.

Santos T., Pinheiro J., Barros P. Cognitive Impairment in Multiple Sclerosis // European Neurological Review. — 2015. — 10(2) — P. 157-63.

Ruano L., Portaccio E., Goretti B. et al. Age and disabi-lity drive cognitive impairment in multiple sclerosis across disease subtypes // Multiple Sclerosis Journal. — 2016. — P. 1-10. DOI: 10.1177/1352458516674367.

Lin S.J., Lam J., Beveridge S., Vavasour I., Traboulsee A., Li D.K.B., MacKay A., McKeown M., Kosaka B. Cognitive Performance in Subjects With Multiple Sclerosis Is Robustly Influenced by Gender in Canonical-Correlation Analysis // Journal of Neuropsychiatry and Clinical Neurosciences. — 2016. — Рublished online. DOI: 10.1176/appi.neuropsych.16040083.

Ross K.A., Schwebel D.C., Rinker J., Ness J., Ackerson J. Neurocognitive sequelae in African American and Caucasian children with multiple sclerosis // Neurology. — 2010. — 75(23). — P. 2097-2102.

Benedict R.H., Morrow S.A., Weinstock Guttman B., Cookfair D., Schretlen D.J. Cognitive reserve moderates decline in information processing speed in multiple sclerosis patients // Journal of the International Neuropsychological Society. — 2010. — 16(5). — P. 829-835. DOI: 10.1017/S1355617710000688.

Sumowski J.F., Leavitt V.M. Cognitive reserve in multiple sclerosis // Multiple Sclerosis. — 2013. — 19. — P. 1122-1127. DOI: 10.1177/1352458513498834.

Moretti R., Morelli M.E., Caruso P. Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact // International Journal of Molecular Sciences. — 2018. — 19(8). — P. 2245. DOI:10.3390/ijms19082245.

Alharbi F.M. Update in vitamin D and multiple sclerosis // Neurosciences (Riyadh). — 2015. — 20(4). — P. 329-335. DOI: 10.17712/nsj.2015.4.20150357.

Khosravi-Largani M., Pourvali-Talatappeh P., Rousta A.M. et al. A review on potential roles of vitamins in incidence, progression, and improvement of multiple sclerosis // eNeurologicalSci. — 2018. — 10. — P. 37-44. DOI: 10.1016/j.ensci.2018.01.007.

Bäärnhielm M., Olsson T., Alfredsson L. Fatty fish intake is associated with decreased occurrence of multiple sclerosis // Multiple Sclerosis Journal. — 2014. — 20(6). — P. 726-32. DOI: 10.1177/1352458513509508.

Schlögl M., Holick M.F. Vitamin D and neurocognitive function // Clinical Interventions in Aging. — 2014. — 9. — P. 559-568. DOI: 10.2147/CIA.S51785.

Morrison J.D., Mayer L. Physical Activity and Cognitive Function in Adults with Multiple Sclerosis: An Integrative Review // Disability and Rehabilitation. — 2017. — 39(19). — P. 1909-1920. DOI: 10.1080/09638288.2016.1213900.

Özcan M.E., Ince B., Bingöl A., Ertürk S., Altınöz M.A., Kara-deli H.H., Koçer A., Asil T. Association between smoking and cognitive impairment in multiple sclerosis // Neuropsychiatric Disease and Treatment. — 2014. — 10. — P. 1715-1719. DOI: 10.2147/NDT.S68389.

Hedström A.K., Hillert J., Olsson T., Alfredsson L. Nicotine might have a protective effect in the etiology of multiple sclerosis // Multiple Sclerosis Journal. — 2013. — 19(8). — P. 1009-1013. DOI: 10.1177/1352458512471879

Moss B.P., Rensel M.R., Hersh C.M. Wellness and the Role of Comorbidities in Multiple Sclerosis // Neurotherapeutics. — 2017. — 14(4). — P. 999-1017. DOI: 10.1007/s13311-017-0563-6.

Brett K., Parker R., Wittenauer S., Hayashida K., Young T., Vincler M. Impact of chronic nicotine on sciatic nerve injury in the rat // Journal of Neuroimmunology. — 2007. — 186 (1–2). — P. 37-44. DOI: 10.1016/j.jneuroim.2007.02.005

Batista S., Zivadinov R., Hoogs M., Bergsland N., Heininen-Brown M., Dwyer M.G., Benedict R.H. Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis // Journal of Neurology. — 2012. — 259(1). — P. 139-146. DOI: 10.1007/s00415-011-6147-1.

Bakirtzis C., Ioannidis P., Messinis L., Nasios G., Konstantinopoulou E., Papathanasopoulos P., Grigoriadis N. The Rationale for Monitoring Cognitive Function in Multiple Sclerosis: Practical Issues for Clinicians // Open Neurology Journal. — 2018. — 12. — P. 31-40. DOI: 10.2174/1874205X01812010031.

Forslin Y., Granberg T., Antwan Jumah A., Shams S., Aspelin P., Kristoffersen-Wiberg M., Martola J., Fredrikson S. Incidence of Radiologically Isolated Syndrome: A Population-Based Study // American Journal of Neurropadiology. — 2016. — 37(6). — P. 1017-1022. DOI: 10.3174/ajnr.A4660.

Migliore S., Ghazaryan A., Simonelli I. et al. Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis Patients with Very Mild Clinical Disability // Behavioural Neurology. — 2017. — 10 p. DOI: 10.1155/2017/7404289.

Ntoskou K., Messinis L., Nasios G., Martzoukou M., Makris G., Panagiotopoulos E., Papathanasopoulos P. Cognitive and Language Deficits in Multiple Sclerosis: Comparison of Relapsing Remitting and Secondary Progressive Subtypes // The Open Neurology Journal. — 2018. — 12. — P. 19-30. DOI: 10.2174/1874205X01812010019.

Matsushita F., Kida H., Tabei K. et al. Clinical significance of cortical lesions in patients with multiple sclerosis: A neuropsychological and neuroimaging study // Brain and Behavior. — 2018. — 8. — e00934. DOI: 10.1002/brb3.934.

Gajofatto A., Turatti M., Bianchi M.R., Forlivesi S., Gobbin F., Azzarà A., Monaco S., Benedetti M.D. Benign multiple sclerosis: physical and cognitive impairment follow distinct evolutions // Acta Neurologica Scandinavica. — 2016. — 133(3). — P. 183-91. DOI: 10.1111/ane.12442.

Roy S., Drake A., Snyder S. et al. Preliminary investigation of cognitive function in aged multiple sclerosis patients: Challenges in detecting comorbid Alzheimer’s disease // Multiple Sclerosis and Related Disorders. — 2018. — 22. — P. 52-56. DOI: 10.1016/j.msard.2018.03.008.

Devere R. Multiple Sclerosis and Mild Cognitive Impairment // Practical Neurology. — 2011 — May/June. — P. 26-31.

Guimarães J., Sá M.J. Cognitive Dysfunction in Multiple Sclerosis // Frontiers in Neurology. — 2012. — 3. — P. 74. DOI: 10.3389/fneur.2012.00074.

Mantos T.S., Pinheiro J., Barros P. Cognitive Impairment in Multiple Sclerosis // European Neurological Review. — 2015. — 10(2). — P. 157-163.

Planche V., Ruet A., Charré Morin J., Deloire M., Brochet B., Tourdias T. Pattern separation performance is decreased in patients with early multiple sclerosis // Brain and Behavior. — 2017. — 7. — e00739. DOI: 10.1002/brb3.739.

Korakas N., Tsolaki M. Cognitive Impairment in Multiple Sclerosis: A Review of Neuropsychological Assessments // Cognitive And Behavioral Neurology. — 2016. — 29(2). — P. 55-67. DOI: 10.1097/WNN.0000000000000097.

Feinstein A., Pavisian B. Multiple sclerosis and suicide // Multiple Sclerosis. — 2017. — 23(7). — P. 923-927. DOI: 10.1177/1352458517702553.

Cecchetto C., Aiello M., D’Amico D., Cutuli D., Carg­nelutti D., Eleopra R., Rumiati R.I. Facial and Bodily Emotion Recognition in Multiple Sclerosis: The Role of Alexithymia and Other Characteristics of the Disease // Journal of the International Neuropsychological Society. — 2014. — 20. — P. 1-11. DOI: 10.1017/S1355617714000939.

Henry A., Bakchine S., Maarouf A., Chaunu M.P. Facial Emotion Recognition and Faux Pas Interpretation in Multiple Sclerosis // Journal of Australasian Society for the Study of Brain Impairment. — 2015. — 16(3). — P. 158-172. DOI: 10.1017/BrImp.2015.33P.

Labbé T., Ciampi E., Rodríguez C.C. Social cognition: Concepts, neural basis and its role in multiple sclerosis // Neurology and Clinical Neuroscience. — 2018. — 6(1). — P. 3-8. DOI:10.1111/ncn3.12164.

Henry A., Tourbah A., Chaunu M.P., Bakchine S., Montreuil M. Social Cognition Abilities in Patients With Different Multiple Sclerosis Subtypes // Journal of the International Neuropsychological Society. — 2017. — 23(8). — P. 653-664. DOI: 10.1017/S1355617717000510.

Jongen P.J., Ter Horst A.T., Brands A.M. Cognitive impairment in multiple sclerosis // Minerva Medica. — 2012. — 103(2). — P. 73-96.

Langdon D. Cognitive Assessment in Multiple Sclerosis // European Neurological Review. — 2018. — 13(1). — P. 12-13. DOI: 10.17925/ENR.2018.13.1.12.

Benedict R.H., Amato M.P., Boringa J. et al. Brief International Cognitive Assessment for MS (BICAMS): international standards for validation // BMC Neurology. — 2012. — 12. — 55. DOI: 10.1186/1471-2377-12-55.

Pinter D., Khalil M., Pichler A. et al. Predictive value of different conventional and nonconventional MRI-parameters for specific domains of cognitive function in multiple sclerosis // NeuroImage: Clinical. — 2015. — 7 — P. 715-720. DOI: 10.1016/j.nicl.2015.02.023.

Prager B.C., Nowacki A.S., Conway D.S. Survey-based assessment of the relationship between cognitive impairment and mentally stimulating activity in multiple sclerosis // A Journal of Progress in Neurosurgery, Neurology and Neurosciences. — 2017. — 39(9). — P. 773-778. DOI: 10.1080/01616412.2017.1348679.

Rocca M.A., Amato M.P., De Stefano N. et al. Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis // The Lancet. Neurology. — 2015. — 14(3). — P. 302-317. DOI: 10.1016/S1474-4422(14)70250-9.

Steenwijk M.D., Geurts J.J., Daams M., et al. Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant // Brain. — 2016. — 139 — P. 115-126. DOI: 10.1093/brain/awv337.

Pravatà E., Rocca M.A., Valsasina P., Riccitelli G.C., Gobbi C., Comi G., Falini A., Filippi M. Gray matter trophism, cognitive impairment, and depression in patients with multiple sclerosis // Multiple Sclerosis Journal. — 2017. — 23(14). — P. 1864-1874. DOI: 10.1177/1352458517692886.

Kappus N., Weinstock-Guttman B., Hagemeier J. et al. Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis // Journal of Neurology, Neurosurgery and Psychiatry. — 2016. — 87. — P. 181-187. DOI: 10.1136/jnnp-2014-310051.

Sumowski J.F., Leavitt V.M. Cognitive reserve in multiple sclerosis // Multiple Sclerosis. — 2013. — 19. — P. 1122-1127. DOI: 10.1177/1352458513498834.

Manouchehrinia A., Tench C.R., Maxted J., Bibani R.H., Britton J., Constantinescu C.S. Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study // Brain. — 2013. — 136 — P. 2298-2304. DOI: 10.1093/brain/awt139.

Amato M.P., Langdon D., Montalban X., Benedict R.H., De Luca J., Krupp L.B., Thompson A.J., Comi G. Treatment of cognitive impairment in multiple sclerosis: position paper // Journal of Neuro-logy. — 2013. — 260(6). — P. 1452-1468. DOI: 10.1007/s00415-012-6678-0.

Toosy A., Ciccarelli O., Thompson A. Symptomatic treatment and management of multiple sclerosis // Handbook of Clinical Neurology. — 2014. — 122. — P. 513-562. DOI: 10.1016/B978-0-444-52001-2.00023-6.

Brandt M.D., Ellwardt E., Storch A. Short- and long-term treatment with modafinil differentially affects adult hippocampal neurogenesis // Neuroscience. — 2014. — 10(278). — P. 267-275. DOI: 10.1016/j.neuroscience.2014.08.014.

Punzin M., Gili T., Petrosini L., Caltagirone C., Spalletta G., Sensi S.L. Modafinil-Induced Changes in Functional Connectivity in the Cortex and Cerebellum of Healthy Elderly Subjects // Frontiers in Aging Neuroscience. — 2017. — Published online. DOI: 10.3389/fnagi.2017.00085.

Mokhber N., Azarpazhooh A., Orouji E. et al. Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial // Journal of the Neurological Sciences. — 2014. — 342 (1–2). — P. 16-20. DOI: 10.1016/j.jns.2014.01.038.

Benešová Y., Tvaroh A. Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE // Therapeutic Advances in Neurological Disorders. — 2017. — 10 (1). — P. 18-32. DOI: 10.1177/1756285616671882.

Feinstein A., Pavisian B. Multiple sclerosis and suicide // Multiple Sclerosis. — 2017. — 23(7). — P. 923-927. DOI: 10.1177/1352458517702553.

Iaffaldano P., Viterbo R.G., Paolicelli D. et al. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study // Public Library of Science: One. — 2012. — 7. — e35843. DOI:10.1371/journal.pone.0035843.

Mattioli F., Stampatori C., Bellomi F., Scarpazza C., Capra R. Natalizumab significantly improves cognitive impairment over three years in MS: pattern of disability progression and preliminary MRI findings // PLoS One. — 2015. — 10(7). — e0131803. DOI: 10.1371/journal.pone.0131803.

Kunkel A., Fischer M., Faiss J., Dähne D., Köhler W., Faiss J.H. Impact of natalizumab treatment on fatigue, mood, and aspects of cognition in relapsing-remitting multiple sclerosis // Front. Neurol. — 2015. — 11, 6. — Р. 97. DOI: 10.3389/fneur.2015.00097.

Roy S., Benedict R.H., Drake A.S., Weinstock-Guttman B. Impact of Pharmacotherapy on Cognitive Dysfunction in Patients with Multiple Sclerosis // CNS Drugs. — 2016. — 30(3) — P. 209-225. DOI: 10.1007/s40263-016-0319-6.

Miller K.J., Dye R.V., Kim J., Jennings J.L., O’Toole E., Wong J., Siddarth P. Effect of a computerized brain exercise program on cognitive performance in older adults // American Journal of Geriatric Psychiatry. — 2013. — 21(7). — P. 655-63. DOI: 10.1016/j.jagp.2013.01.077.

Orzechowska A., Filip M., Gałecki P. Influence of Pharmacotherapy on Cognitive Functions in Depression: A Review of the Li-terature // Medical Science Monitor. — 2015. — 21. — P. 3643-3651. DOI: 10.12659/MSM.895156.

Lovera J.F., Kim E., Heriza E. et al. Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial // Neurology. — 2012. — 79(12). — P. 1278-1284. DOI: 10.1212/WNL.0b013e31826aac60.

Di Bari M., Reale M., Di Nicola M. et al. Dysregulated Homeostasis of Acetylcholine Levels in Immune Cells of RR-Multiple Sclerosis Patients // INT J. Mol. Sci. — 2016. — 17(12). — 2009. — DOI: 10.3390/ijms17122009.

Di Bari M., Di Pinto G., Reale M., Mengod G., Tata A.M. Cholinergic System and Neuroinflammation: Implication in Multiple Sclerosis // Cent. Nerv. Syst. Agents Med. Chem. — 2017. — 17(2). — P. 109-115. DOI: 10.2174/1871524916666160822115133.

Nizri E., Irony-Tur-Sinai M., Faranesh N. et al. Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine // J. Neuroimmunol. — 2008. — 203. — P. 12-22. DOI: 10.1016/j.jneuroim.2008.06.018.

Amenta F., Carotenuto A., Fasanaro A.M., Rea R., Traini E. The ASCOMALVA (Association between the Cholinesterase Inhibitor Donepezil and the Cholinergic Precursor Choline Alphoscerate in Alzheimer’s Disease) Trial: interim results after two years of treatment // J. Alzheimers Dis. — 2014. — 42(3). — P. 281-288. DOI: 10.3233/JAD-140150.

Tayebati S.K., Martinelli I., Moruzzi M., Amenta F., Tomassoni D. Choline and Choline alphoscerate Do Not Modulate Inflammatory Processes in the Rat Brain // Nutrients. — 2017. — 9. — 1084. DOI: 10.3390/nu9101084.

Christodoulou C., MacAllister W.S., McLinskey N.A., Krupp L.B. Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option? // CNS Drugs. — 2008. — 22(2). — P. 87-97. DOI: 10.2165/00023210-200822020-00001.

Krupp L.B., Christodoulou C., Melville P. et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis // Neurology. — 2011. — 76(17). — P. 1500-1507. DOI: 10.1212/WNL.0b013e318218107a.

Messinis L., Papathanasopoulos P., Kosmidis M.H., Nasios G., Kambanaros M. Neuropsychological Features of Multiple Sclerosis: Impact and Rehabilitation // Behavioural Neurology. — 2018. — 4 p. DOI:10.1155/2018/4831647.

Hulst H.E., Goldschmidt T., Nitsche M.A. et al. rTMS affects working memory performance, brain activation and functional connectivity in patients with multiple sclerosis // Journal of Neurology, Neurosurgery & Psychiatry. — 2017. — 88(5). — P. 386-394. DOI: 10.1136/jnnp-2016-314224.

Miller E., Morel A., Redlicka J., Miller I., Salukc J. Pharmacological and Non-pharmacological Therapies of Cognitive Impairment in Multiple Sclerosis // Current Neuropharmacology. — 2018. — 16(4). — P. 475-483. DOI: 10.2174/1570159X15666171109132650.




Copyright (c) 2019 INTERNATIONAL NEUROLOGICAL JOURNAL

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2019

 

   Seo анализ сайта